 Mitumomab

Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination.Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system.